TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...